Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vantictumab + docetaxel
- Development stage
- Unknown
- Lead developer
- Ashio
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Vantictumab + docetaxel is an investigational combination therapy being studied primarily for the treatment of advanced solid tumors, notably non-small cell lung cancer (NSCLC). Vantictumab is a first-in-class monoclonal antibody that targets the Wnt signaling pathway, specifically acting as an antagonist of Frizzled family receptors, which are implicated in the self-renewal and maintenance of cancer stem cells. Docetaxel is a standard-of-care antineoplastic agent classified as a taxane, which acts by stabilizing microtubules and inhibiting cell division. Preclinical and early clinical data suggest this combination exhibits synergistic antitumor activity, with optimal effects seen when vantictumab is administered prior to docetaxel. The combination is being developed by OncoMed Pharmaceuticals (in collaboration with Bayer for some studies) and assessed in clinical trials for safety, pharmacokinetics, and preliminary efficacy, mainly in recurrent or advanced NSCLC and other solid tumors[1][2][3][4][5].
- Other names
- vantictumab and docetaxel
02
Targets
FZD5 (Frizzled receptor 5)FZD2 (Frizzled Receptor 2)FZD8 (Frizzled Receptor 8)FZD1 (Frizzled Receptor 1)TUBB (Tubulin (alpha and beta subunits))FZD7 (Frizzled class receptor 7)
Beyond the preview
Go deeper on vantictumab + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vantictumab + docetaxel.